NCT05612581 - A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

May 10, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions

Hepatitis B, Chronic

Interventions

DRUG

VIR-3434

VIR-3434 given by subcutaneous injection

DRUG

VIR-2218

VIR-2218 given by subcutaneous injection

DRUG

TDF

TDF given orally

DRUG

PEG-IFNα

PEG-IFNα given by subcutaneous injection

Trial Locations (15)

5505

Investigative Site, Seoul

31000

Investigative Site, Toulouse

35000

Investigative Site, Rennes

49241

Investigative Site, Busan

50612

Investigative Site, Yangsan

92110

Investigative Site, Clichy

06200

Investigative Site, Nice

Unknown

Investigative Site, Hong Kong

MD 2025

Investigative Site, Chisinau

021105

Investigative Site, Bucharest

G4 0SF

Investigative Site, Glasgow

EC1A 7BE

Investigative Site, London

SE5 9RS

Investigative Site, London

M8 5RB

Investigative Site, Manchester

All Listed Sponsors

lead

Vir Biotechnology, Inc.

INDUSTRY